entertainment -WSS

entertainment

author：fashion 2025-09-27 12:47:45 - browse：23388

Eli Lilly headquarters — Kristoffer Tripplaar/AP

SAN DIEGO – An experimental pill from Eli Lilly led to 14.7% weight loss on the highest dose in a 36-week trial, heating up the growing competition among drugmakers to develop an effective oral obesity therapy.

The mid-stage results for orforglipron match the estimates of 14-15% weight loss that Lilly gave in an investor call late last year. The full results, published Friday in the New England Journal of Medicine, were presented here to a packed conference room at the American Diabetes Association conference.

By the end of trial, the authors said, participants’ weight loss had not plateaued, suggesting potential for even greater weight loss over a longer treatment period.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Complete sequence of Y chromosome published for first time

WSS

Can CDC director Mandy Cohen drive consensus in Washington?

J&J expands global access to TB drug amid advocacy campaign

Everything to know for the next Powerball drawing as jackpot hits $1 billion

FDA panel gives mixed vote on blood pressure devices

CDC advisory panel says seniors 'may' get RSV vaccine

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

focus

entertainment

knowledge

As demand for Covid shots wanes, Moderna seeks its next success

Grail faces three suits alleging harassment, retaliation

The cancer drug shortage isn’t new — and neither are the solutions

Complete sequence of Y chromosome published for first time

Continuity nursing helped my family in our darkest PICU moments

Mike Pence clashes with Tucker Carlson in Iowa

Cancer drug shortages should be causing more outrage

Eli Lilly to acquire Versanis in heated race for weight loss drugs

Malaria cases in Florida and Texas: Here’s what you need to know

RFK Jr. accused of antisemitic claims about COVID but insists he was misunderstood

explore

Argenx drug significantly slows progression of nerve disorder

Complete sequence of Y chromosome published for first time

What AAP's gender

J&J expands global access to TB drug amid advocacy campaign

Study finds new variant for Parkinson’s in African populations

Feds fine Medicare Advantage plans for overcharging members

focus

entertainment

leisure time

focus